Regeneron stops pancreatic cancer trial

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY) ended the Phase III VANILLA trial of aflibercept to treat metastatic pancreatic cancer after interim data showed the compound plus gemcitabine would not meet the primary endpoint of overall survival vs. placebo plus gemcitabine. Regeneron said no decision had been made on aflibercept's future development in the indication. ...